Shield Across America

Mobilizing the Mission to Increase Colon Cancer Screening — Coast to Coast.

View tour stops

Screen for colon cancer with Shield™— it's just a blood test!

From Guardant Health, a trusted leader in blood tests for cancer for more than a decade.

Get Started Now

What is Shield Across America?

What is
Shield Across America?

Shield Across America is a nationwide movement to help increase colon cancer screening.

We’re bringing colorectal cancer screening awareness and education about the Shield blood test directly to communities. At tour stops, visitors can explore interactive experiences and learn how screening can be done with just a blood test — no at-home kit or stool handling.

Screening with Shield requires a valid clinician order and blood draw. Blood draws may be available at select stops with a valid clinician order.

Learn More About Shield

>50,000

Americans die from colon cancer each year1

75%

of those who die weren't up to date with screening2

50 States

Shield is available across the U.S. and Puerto Rico

Tour stops

We’re traveling to communities across the country to spread the word about the importance of timely colon cancer screening. Check back often, as new cities and tour dates are added!

Las Vegas, NV

Las Vegas, NV

Las Vegas, NV

Nashville, TN

Nashville, TN

Nashville, TN

  • Tin Pan South Songwriters Festival
    March 24-28, 2026

Request a stop

Bring the Shield blood test to your community.

Frequently asked questions

Quick answers about the tour and next steps.

Shield is a blood test that screens for colon cancer. It starts with just a blood draw, and can easily be part of your routine blood testing that your healthcare provider orders.

  • Shield is intended for patients who are 45 years of age and older, show no symptoms, and are at average risk for colon cancer.
  • Patients with a positive result should be followed by colonoscopy.
  • Discuss colorectal cancer screening options with your healthcare provider to determine the best screening method for you.

You can ask your healthcare provider if you are eligible to screen with Shield. Your healthcare provider can then order Shield and you can get a blood draw either at their office or at a nearby lab. You will receive your results in approximately two weeks.

When screening for colon cancer, you have options, including colonoscopy, stool-based tests, and the Shield blood test. You may be eligible for Shield if you are 45 or older, at average risk for colon cancer, and due for colon cancer screening.

Check if you’re eligible

Ask your healthcare provider if you can screen for colon cancer with the Shield blood test. Shield is available by prescription only.

Don’t wait. Get screened today.

Ask your doctor about the Shield blood test for colon cancer screening—from the company trusted in blood tests for cancer for over a decade.

Get Started Now

Important Product Information

Intended Use

The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit.
Shield is intended for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stages II, III, and IV colorectal cancer.

Limitations and Other Important Information: The Shield test is not intended for patients that have personal history of colorectal cancer, adenomas, or other related cancers; or those who had a positive result on another colorectal cancer screening method within the last six months, have been diagnosed with a condition associated with high risk for colorectal cancer such as Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn’s disease; or who have a family history of colorectal cancer, or certain hereditary syndromes. Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. Shield may produce a false negative or false positive result. A false negative result may occur when the Shield test does not detect a colorectal tumor signal while a colonoscopy identifies a colorectal cancer. A negative result does not guarantee the absence of colorectal cancer or advanced adenoma, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline-recommended intervals. A false positive result may occur when the Shield test generates a positive result while a colonoscopy will not find colorectal cancer or advanced adenoma.

Please read our Provider Brochure for complete product information about the Shield test including full safety information.

  1. References:
  2. National Cancer Institute. Cancer Stat Facts: Colorectal Cancer. Accessed May 7, 2024. https://seer.cancer.gov/statfacts/html/colorect.html
  3. Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. Gastroenterology. 2019;156(1):63-74. doi:10.1053/j.gastro.2018.09.040